

# TABLE OF CONTENTS

<b>Cardiology I</b> .....	1
Cardiology I Panel .....	3

## Hypertension

*By Toni L. Ripley, Pharm.D., FCCP, BCPS, AHSCP-CHC; and Anna Barbato, Pharm.D., BCPS, AHSCP-CHC*

Introduction .....	7
Clinical Guideline Update .....	8
Treatment Goals .....	10
Blood Pressure Measurement .....	12
Drug Therapy .....	13
Hypertensive Crisis .....	18
Secondary Hypertension .....	18
Difficult-to-Treat Hypertension .....	19
Conclusion .....	23
References .....	23
Self-Assessment Questions .....	26

## Dyslipidemia

*By Craig J. Beavers, Pharm.D., BCCP, CACP; and Michael S. Kelly, Pharm.D., BCACP, CDE, CLS*

Introduction .....	31
Review of Current Guidelines for Dyslipidemia Management .....	31
New Evidence for Non-statin Therapies in Preventing ASCVD .....	38
Defining and Managing Statin Intolerance .....	40
Statins and DM Risk .....	44
Select Special Populations .....	44
Emerging Therapies .....	47
Conclusion .....	48
References .....	49
Self-Assessment Questions .....	52

<b>Cardiology II</b> .....	57
Cardiology II Panel .....	59

## Acute Coronary Syndrome/Acute Myocardial Infarction

*By James C. Coons, Pharm.D., FCCP, BCCP; and Taylor Miller, Pharm.D.*

Introduction .....	63
Advances in PCI .....	65
Oral and Intravenous Antiplatelets .....	65
“Real-world” Study and Head-to-Head Comparisons .....	69
Summary .....	69
Personalized Medicine Approaches .....	69

Anticoagulants .....	75
Other Pharmacotherapy for ACS .....	76
Clinical Performance and Quality Measures .....	77
Conclusion .....	79
References .....	79
Self-Assessment Questions .....	84

## Heart Failure

*By Adam Sieg, Pharm.D., BCPS*

Introduction .....	87
Renin-Angiotensin-Aldosterone System .....	91
Sympathetic Activation .....	94
Alternative Agents .....	95
Novel HF Therapies .....	95
Inotropic Therapy .....	97
Advanced Therapy Modalities .....	98
Current HF Medications .....	98
HF Therapies with Limited Benefit or Potential Harm .....	101
Conclusion .....	103
References .....	103
Self-Assessment Questions .....	106

## Complex Management of Atrial Fibrillation

*By Bethany A. Kalich, Pharm.D., BCPS-AQ Cardiology*

Introduction .....	111
VHD and AF .....	115
Triple Antithrombotic Therapy .....	118
OAC Regimens for AF-Related Procedures .....	119
Perioperative Management of OAC .....	122
Role of the Pharmacist .....	123
Conclusion .....	124
References .....	124
Self-Assessment Questions .....	128

<b>Cardiology III</b> .....	131
Cardiology III Panel .....	133

## Recorded Webcast: Precision Medicine in Cardiovascular Disease

*By James C. Lee, Pharm.D., BCACP; and Yee Ming Lee, Pharm.D., BCPS, ABCP*

Recorded Webinar: Precision Medicine in Cardiovascular Disease .....	138
References .....	138
Self-Assessment Questions .....	141

### Recorded Webcast: Valvular Heart Disease

*By Carrie S. Oliphant, Pharm.D., FCCP, BCPS, BCCP, AACC;  
and J. Erin Ledford, Pharm.D., BCPS AQ-Cardiology, BCCCP*

Recorded Webinar: Valvular Heart Disease .....	146
References .....	146
Self-Assessment Questions .....	148

### Cardiology IV .....

Cardiology IV Panel .....	153
---------------------------	-----

### Recorded Webinar: Meta-analysis and Observational Research in Cardiovascular Disease

*By William L. Baker Jr, Pharm.D., FCCP, FACC, FAHA*

Recorded Webinar: Meta-analysis and Observational Research in Cardiovascular Disease .....	158
References .....	158
Self-Assessment Questions .....	159

### Statistics in Practice: Statistics Overview

*By Ryan Rodriguez, Pharm.D., BCPS;  
and Daniel R. Touchette, Pharm.D., M.A., FCCP*

References .....	164
Self-Assessment Questions .....	165